| Family: | Blackrock (iShares) |
| Name: | iShares Neuroscience and Healthcare ETF |
| Inception Date: | 24-Aug-2022 |
| Termination Date: | |
| Investment Objective: | The iShares Neuroscience and Healthcare ETF seeks to track the investment results of an index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience. Proviedes exposure to global stocks involved in the research, development and treatment of neurological disorders. |
| Prospectus | |
| Top 10 Holdings | ||
| DIANTHUS THERAPEUTICS INC | DNTH | 5.0305% |
| PRAXIS PRECISION MEDICINES INC | PRAX | 4.9927% |
| XENON PHARMACEUTICALS INC | XENE | 4.9324% |
| ALKERMES | ALKS | 4.8191% |
| ARROWHEAD PHARMACEUTICALS INC | ARWR | 4.5649% |
| ACADIA PHARMACEUTICALS INC | ACAD | 4.3698% |
| PTC THERAPEUTICS INC | PTCT | 4.2230% |
| SCHOLAR ROCK HOLDING CORP | SRRK | 4.1968% |
| NEUROCRINE BIOSCIENCES INC | NBIX | 4.1802% |
| AXSOME THERAPEUTICS INC | AXSM | 4.0440% |
| Top 10 Holdings Weight: | 45.4% |
| Number of Holdings: | 79 |
| Shares Outstanding: | 150,000 |
| Total Net Assets: | 5,657,730 |
| NAV: | 37.61 |
| Net Expense Ratio: | 0.47% |
| Asset Class: | Equities (Stocks) |
| Developed or Emerging: | Developed Market Funds |
| Country: | |
| Region: | |
| Strategy: | |
| Currency: | |
| Commodity: | |
| Sector: | Healthcare |
| Industry: | |
| Dividend Type: | |
| Tax Exempt State: | |
| Maturity Duration: | |
| Market Cap: | Broad Market / Multi-Cap |
| Credit Quality: | |
| Mortgage Bond Types: | |
| Bond Type: | |
| Gov't Bond Types: | |
| Reit Type: | |
| Leverage Direction/Factor: | |
| Is Currency Hedged: | No |
| US or Ex-US: | Global |
